Clinical Trials Logo

Recurrent Cervical Carcinoma clinical trials

View clinical trials related to Recurrent Cervical Carcinoma.

Filter by:

NCT ID: NCT03968406 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Start date: September 26, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous treatment (recurrent). Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib in combination with radiation therapy may work better in treating patients with gynecologic cancers.

NCT ID: NCT03170570 Recruiting - Cervical Cancer Clinical Trials

the Re-irradiation of Recurrent Cervical Cancer by IMRT

Start date: December 1, 2016
Phase: N/A
Study type: Interventional

this is a prospective clinical trial using intensity modulated radiotherapy(IMRT)for the treatment of cervical cancer patients with recurrent disease within the previously irradiated field. Sixty patients will be enrolled after careful selection to meet the including criteria and excluding criteria. A primary course of 36Gy will be prescribed to the recurrent site and a further 9-24Gy of dose escalation will be prescribed to the gross tumor volume in the second course according to the toxicities and the shrinkage of tumor. Weekly concurrent cisplatin of 30mg/m2 by five weeks will be administrated intravenously to the selected patients. Acute and late toxicities will be monitored and survival endpoints will be tracked with our follow-up protocol to evaluate the safety and efficacy of this approach.